Marshall Wace LLP Raises Stock Holdings in Dynavax Technologies Corporation $DVAX

Marshall Wace LLP grew its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 107.2% during the second quarter, Holdings Channel reports. The institutional investor owned 1,814,934 shares of the biopharmaceutical company’s stock after buying an additional 939,076 shares during the period. Marshall Wace LLP’s holdings in Dynavax Technologies were worth $18,004,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in DVAX. Caitong International Asset Management Co. Ltd increased its holdings in Dynavax Technologies by 5,485.7% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,304 shares in the last quarter. Callan Family Office LLC bought a new position in shares of Dynavax Technologies in the second quarter worth approximately $107,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Dynavax Technologies in the second quarter worth approximately $121,000. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Dynavax Technologies in the second quarter worth $127,000. Finally, Baird Financial Group Inc. bought a new stake in shares of Dynavax Technologies during the 2nd quarter valued at $136,000. 96.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DVAX has been the topic of a number of analyst reports. JMP Securities restated a “market outperform” rating and set a $32.00 target price on shares of Dynavax Technologies in a research note on Friday, August 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $24.33.

Dynavax Technologies Trading Down 0.7%

Dynavax Technologies stock opened at $10.89 on Wednesday. Dynavax Technologies Corporation has a 1 year low of $9.20 and a 1 year high of $14.63. The firm’s 50 day moving average price is $10.61 and its 200-day moving average price is $10.40. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. The stock has a market cap of $1.28 billion, a P/E ratio of -29.43 and a beta of 0.89.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. The firm had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. On average, equities analysts predict that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.